APOE and type 1 diabetes mellitus: In a murine model of diabetes-accelerated atherosclerosis, apolipoprotein E (apoE)-deficient mice treated with streptozotocin (type 1 diabetes) or bred into the db/db background (type 2 insulin-resistant diabetes), the administration of sRAGEs has been shown to significantly reduce the progression of atherosclerosis [94].